Key Takeaways & Executive Findings
- •• Gut microbiota dysbiosis in NAFLD is characterized by increased pro-inflammatory bacteria and decreased anti-inflammatory bacteria, contributing to disease progression via the gut-liver axis. • Modulating gut microbiota through probiotics or fecal microbiota transplantation reduces transaminase levels and inflammation, highlighting gut microbiota as a therapeutic target. • Exercise modulates gut microbiota composition and function, increasing beneficial bacteria and reducing pro-inflammatory species, thereby improving host metabolic health. • Exercise exerts beneficial effects on NAFLD through multiple mechanisms involving short-chain fatty acids, bile acid metabolism, lipopolysaccharide reduction, and indole derivatives.
Abstract
BACKGROUND: The pathogenesis of non-alcoholic fatty liver disease is closely associated with gut microbiota dysbiosis. In recent years, accumulating evidence has indicated that exercise may exert beneficial effects on host metabolic homeostasis by modulating the composition and function of the gut microbiota, thereby playing a positive role in the prevention and treatment of non-alcoholic fatty liver disease. OBJECTIVE: To systematically summarize current research progress on the interplay between gut microbiota and non-alcoholic fatty liver disease, to further elucidate the regulatory effects of exercise on gut microbiota, and to explore in depth the potential mechanisms by which exercise intervention may prevent or ameliorate non-alcoholic fatty liver disease via the "gut–liver axis." METHODS: Search terms included "non-alcoholic fatty liver disease," "gut microbiota," "exercise," "bile acid," "short-chain fatty acid," "lipopolysaccharide," "trimethylamine oxide," and "indole" in Chinese and English, respectively. China National Knowledge Infrastructure (CNKI), and WanFang Database were searched for relevant studies published up to March 2025. A total of 85 core studies were identified based on the inclusion and exclusion criteria. RESULTS AND CONCLUSION: (1) The composition of gut microbiota in patients with non-alcoholic fatty liver disease is significantly abnormal, with increased abundance of pro-inflammatory bacteria (such as Proteobacteria, Escherichia coli, and Streptococcus) and pathogenic bacteria (such as Enterobacteriaceae), while the abundance of anti-inflammatory and homeostatic bacteria (such as Ruminococcus and Faecalibacterium) is decreased. These adverse changes in microbial composition may promote the entry of metabolites into the liver by increasing intestinal permeability, activating inflammatory pathways, and increasing endogenous ethanol production, thereby driving the pathological progression of non-alcoholic fatty liver disease. (2) Modulating gut microbiota through probiotic supplementation or fecal microbiota transplantation can effectively reduce transaminase levels and chronic inflammation in patients with non-alcoholic fatty liver disease, suggesting that gut microbiota may be an important target for the prevention and treatment of non-alcoholic fatty liver disease. (3) Exercise can regulate gut microbiota composition, increase the abundance of beneficial bacteria, reduce the abundance of pro-inflammatory bacteria, and promote the activation of key metabolic pathways, thereby improving host metabolic health. However, current research on the effects of exercise on gut microbiota in patients with non-alcoholic fatty liver disease remains relatively limited, especially the effects and mechanisms of different exercise types, intensities, and durations on gut microbiota and host metabolism are still unclear. (4) Exercise may regulate gut microbiota and increase short-chain fatty acid production to activate G protein-coupled receptors 41/43 and AMP-activated protein kinase pathways, inhibit histone deacetylase activity, thereby reducing hepatic fat accumulation, alleviating liver inflammation, and decreasing insulin resistance; exercise may regulate the gut microbiota-bile acid axis to improve bile acid metabolism, thereby mediating the farnesoid X receptor/G protein-coupled bile acid receptor 5 signaling pathway to prevent and treat non-alcoholic fatty liver disease; exercise may reshape gut microbiota to reduce the abundance of lipopolysaccharide-containing Gram-negative bacteria and improve intestinal barrier function to reduce lipopolysaccharide production and translocation, preventing and treating non-alcoholic fatty liver disease; exercise may regulate gut microbiota composition to enhance the synthesis of indole and its derivatives, while inhibiting the production of ethanol and trimethylamine oxide, thereby enhancing liver metabolic capacity, improving intestinal barrier function, and reducing liver inflammation, playing a positive role in the prevention and treatment of non-alcoholic fatty liver disease.
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive fat deposition in the liver in the absence of significant alcohol intake. With the global rise in obesity and type 2 diabetes, the incidence of NAFLD has increased rapidly, affecting an estimated 25% of the world's population. The disease can progress from simple steatosis to non-alcoholic steatohepatitis, potentially leading to fibrosis, cirrhosis, and hepatocellular carcinoma. Due to its insidious nature, chronic progression, and high mortality, NAFLD has become a leading cause of liver-related death and transplantation. Therefore, understanding its pathological mechanisms is crucial for developing targeted prevention and treatment strategies.
The gut microbiota, a vast microbial community residing in the intestinal tract, plays a complex symbiotic role with the host, participating in metabolism, immune regulation, and nutrient absorption. In the pathogenesis of NAFLD, gut dysbiosis is considered a key driver. The "gut-liver axis" theory provides a framework for understanding how intestinal microbial alterations contribute to liver disease. This review systematically summarizes the interplay between gut microbiota and NAFLD, and explores the potential mechanisms by which exercise, through modulation of the gut microbiota, may prevent or ameliorate NAFLD.
Loading authentic research manuscript (Pages 1–5)...
WANG Wei, CHEN Jun, JIA Shaohui, XUE Xinxuan, DONG Kunwei (2026). Mechanisms by which exercise regulates gut microbiota in the prevention and treatment of non-alcoholic fatty liver disease. Chinese Journal of Tissue Engineering Research. https://doi.org/10.12307/2026.21301
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the role of gut microbiota in non-alcoholic fatty liver disease?
Gut microbiota dysbiosis, characterized by increased pro-inflammatory bacteria and decreased anti-inflammatory bacteria, contributes to NAFLD progression by increasing intestinal permeability, activating inflammatory pathways, and promoting endogenous ethanol production.
How does exercise affect gut microbiota in NAFLD?
Exercise modulates gut microbiota composition by increasing beneficial bacteria and reducing pro-inflammatory species, thereby improving host metabolic health and potentially preventing or ameliorating NAFLD.
What are the key mechanisms by which exercise prevents NAFLD via gut microbiota?
Exercise may increase short-chain fatty acid production, regulate bile acid metabolism, reduce lipopolysaccharide translocation, and enhance indole derivatives, all of which contribute to reduced hepatic fat accumulation, inflammation, and insulin resistance.
Can modulating gut microbiota be a therapeutic strategy for NAFLD?
Yes, studies show that probiotic supplementation or fecal microbiota transplantation can reduce transaminase levels and inflammation in NAFLD patients, indicating that gut microbiota is a promising therapeutic target.
What are the limitations of current research on exercise and gut microbiota in NAFLD?
Research on the effects of exercise on gut microbiota in NAFLD patients is limited, and the specific impacts of different exercise types, intensities, and durations on gut microbiota and host metabolism remain unclear.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.